Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal.

[1]  M. Yanagawa,et al.  Association Of Serum Tumour Necrosis Factor‐α With Serum Low‐Density Lipoprotein–Cholesterol And Blood Pressure In Apparently Healthy Japanese Women , 2001, Clinical and experimental pharmacology & physiology.

[2]  M. Irahara,et al.  Postmenopausal changes in serum cytokine levels and hormone replacement therapy. , 2001, American journal of obstetrics and gynecology.

[3]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[4]  M. J. Toth,et al.  Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. , 2000, Diabetes care.

[5]  D. Matthews,et al.  Regulation of protein metabolism in middle-aged, premenopausal women: roles of adiposity and estradiol. , 2000, The Journal of clinical endocrinology and metabolism.

[6]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[7]  H. Schunkert,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Hormone Replacement Therapy and Interrelation between Serum Interleukin-6 and Body Mass Index in Postmenopausal Women: A Population-Based Study , 2022 .

[8]  E. Poehlman,et al.  Effect of menopausal status on body composition and abdominal fat distribution , 2000, International Journal of Obesity.

[9]  J. Callés-Escandon,et al.  Relation of regional fat distribution to insulin sensitivity in postmenopausal women. , 2000, Fertility and Sterility.

[10]  J. Gustafsson,et al.  Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[12]  E. Poehlman,et al.  Sex hormone-binding globulin levels in middle-aged premenopausal women. Associations with visceral obesity and metabolic profile. , 1999, Diabetes care.

[13]  C. Tsigos,et al.  Circulating tumor necrosis factor alpha concentrations are higher in abdominal versus peripheral obesity. , 1999, Metabolism: clinical and experimental.

[14]  E. Barrett-Connor,et al.  Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. , 1999, Circulation.

[15]  J. Manson,et al.  Hormone replacement therapy and increased plasma concentration of C-reactive protein. , 1999, Circulation.

[16]  E. Poehlman,et al.  Hormonal and physiological correlates of energy expenditure and substrate oxidation in middle-aged, premenopausal women. , 1999, The Journal of clinical endocrinology and metabolism.

[17]  A. Hofman,et al.  Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[18]  H. Cohen,et al.  Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. , 1999, The American journal of medicine.

[19]  M. McCarty.  Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. , 1999, Medical hypotheses.

[20]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[21]  E. Barrett-Connor,et al.  Hormone replacement therapy , 1998, BMJ.

[22]  J. S. Hunt,et al.  Regulation of TNF-alpha production in activated mouse macrophages by progesterone. , 1998, Journal of immunology.

[23]  A. Greenberg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Omental and Subcutaneous Adipose Tissues of Obese Subjects Release Interleukin-6: Depot Difference and Regulation by Glucocorticoid* , 1997 .

[24]  C. Sites.  Hormone replacement therapy: cardiovascular benefits for aging women. , 1998, Coronary artery disease.

[25]  L. Kuller,et al.  Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[26]  R. Tracy,et al.  Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. , 1997, Clinical chemistry.

[27]  R. Henry,et al.  The expression of TNF alpha by human muscle. Relationship to insulin resistance. , 1996, The Journal of clinical investigation.

[28]  E. Poehlman,et al.  Changes in Energy Balance and Body Composition at Menopause: A Controlled Longitudinal Study , 1995, Annals of Internal Medicine.

[29]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[30]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.